Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech which has proved helpful conscientiously but unsuccessfully to develop a single therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this treatment, CytoDyn has cast its net far and wide both geographically and in terms of possible indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination therapy in the treatment of multi-drug-resistant HIV are actually closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the last few shares of mine. The first CytoDyn post of mine, “CytoDyn: What In order to Do When It is Too Good In order to Be True?”, set out the following prediction:

Rather I expect it to be a serial disappointer. CEO Pourhassan presented such a very promotional picture in the Uptick Newswire employment interview that I came away with a poor viewpoint of the company.

Irony of irony, my poor viewpoint of the company has grown steadily, although the disappointment has not been financial. 2 many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is it that gives a > 6 bagger yet still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall refer to as leronlimab) back in 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) targeting the CCR5 receptor for your treatment as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise as well as associated intellectual property coming from Progenics to CytoDyn, and roughly 25 million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) and the first brand new drug program endorsement ($five million), and even royalty payments of five percent of net sales after commercialization.

Since that time, CytoDyn’s leading nous, Nader Pourhassan [NP] has transformed this inauspicious acquisition right into a springboard for CytoDyn to buy a sector cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous indications and multiple therapies, it has this individual therapies as well as a “broad pipeline of indications” because it places it. I call certain pipelines, “pipedots.” In CytoDyn’s case it touts the leronlimab of its as a potentially beneficial therapy in dozens of indications.

The opening banner of its on the site of its (below) shows an energetic company with diverse interests albeit centered on leronlimab, several illness sorts, multiple presentations and multiple publications.

Might it all be smoke and mirrors? That is a question I have been asking myself through the very beginning of the interest of mine in this organization. Judging by way of the multiples of a huge number of various comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am a lot from alone in this question.

CytoDyn is a traditional battleground, or possibly some might say cult inventory. Its adherents are fiercely protective of its prospects, quick to label any negative opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *